• 1
    Dacie JV. Paroxysmal nocturnal haemoglobinuria. Proc R Soc Med 1963; 56: 587596.
  • 2
    Oni SB, Osunkoya BO, Luzzatto L. Paroxysmal nocturnal hemoglobinuria: Evidence for monoclonal origin of abnormal red cells. Blood 1970; 36: 145152.
  • 3
    Parker CJ. Historical aspects of paroxysmal nocturnal haemoglobinuria: ‘Defining the disease’. Br J Haematol 2002; 117: 322.
  • 4
    Miyata T, Takeda J, Iida Y, Yamada N, Inoue N, Takahashi M, Maeda K, Kitani T, Kinoshita T. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science 1993; 259: 13181320.
  • 5
    Takeda J, Miyata T, Kawagoe K, Iida Y, Endo Y, Fujita T, Takahashi M, Kitani T, Kinoshita T. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993; 73: 703711.
  • 6
    Nicholson-Weller A, March JP, Rosenfeld JP, Austen KF. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay acceleration factor. Proc Natl Acad Sci USA 1983; 80: 50665070.
  • 7
    Holguin MH, Frederick LR, Bernshaw NJ, Wilcox LA, Parker CJ. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest 1989; 84: 717.
  • 8
    Rosse WF, Ware RE. The molecular basis of paroxysmal nocturnal hemoglobinuria. Blood 1995; 86: 32773268.
  • 9
    Nafa K, Bessler M, Castro-Malaspina H, Jhanwar S, Luzzatto L. The spectrum of somatic mutations in the PIG-A gene in paroxysmal nocturnal hemoglobinuria includes large deletions and small duplications. Blood Cells Mol Dis 1998; 24: 370384.
  • 10
    Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995; 333: 12531258.
  • 11
    Parker CJ. Bone marrow failure syndromes: Paroxysmal nocturnal hemoglobinuria. Hematol Oncol Clin North Am 2009; 23: 333346.
  • 12
    Galili N, Ravandi F, Palermo G, Bubis J, Illingworth A, Castro-Malaspina H, Raza A. Prevalence of paroxysmal nocturnal hemoglobinuria (PNH) cells in patients with myelodysplastic syndromes (MDS), aplastic anemia (AA) or other bone marrow failure (BMF) syndromes: Interim results from the EXPLORE trial. J Clin Oncol 2009; 27: 15s (abstract).
  • 13
    Shih A, Chin-Yee I, Hedley B, Keeney M, Wells R, Sutherland D R, Hsia CC. Screening patients with myelodysplastic syndrome and aplastic anemia for paroxysmal nocturnal hemoglobinuria clones: A retrospective study. Blood 2011; suppl 1 (abstract).
  • 14
    Movalia MK, Weitz IC, Lim SH, Illingworth A. Incidence of PNH clones by diagnostic code utilizing high sensitivity flow cytometry. Blood 2011; suppl 1 (abstract).
  • 15
    Sugimori C, Chuhjo T, Feng X, Yamazaki H, Takami A, Teramura M, Mizoguchi H, Omine M, Nakao S. Minor population of CD55–CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood 2006; 107; 13081314.
  • 16
    Dunn DE, Tanawattanacharoen P, Boccuni P, Nagakura S, Green SW, Kirby MR, Kumar MS, Rosenfeld S, Young NS. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med 1999; 131: 401408.
  • 17
    Tichelli A, Gratwohl A, Nissen C, Speck B. Late clonal complications in severe aplastic anemia. Leuk Lymphoma 1994; 12: 167175.
  • 18
    van der Schoot CE, Huizinga TW, van't Veer-Korthof ET, Wijmans R, Pinkster J, von dem Borne AE. Deficiency of glycosyl-phosphatidylinositol-linked membrane glycoproteins of leukocytes in paroxysmal nocturnal hemoglobinuria, description of a new diagnostic cytofluorometric assay. Blood 1990; 76: 18531859.
  • 19
    Hall SE, Rosse WF. The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria. Blood 1996; 87: 53325340.
  • 20
    Richards SJ, Rawstron AC, Hillmen P. Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria. Cytometry 2000; 42: 223233.
  • 21
    Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R, Hillmen P, Luzzatto L, Young N, Kinoshita T, Rosse W, Socie G. International PNH Interest Group. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005; 106: 36993709.
  • 22
    Sutherland DR, Kuek N, Azcona-Olivera J, Anderson T, Acton E, Barth D, Keeney M. Use of FLAER-based white blood cell assay in the primary screening of PNH clones. Am J Clin Pathol 2009; 132: 564572.
  • 23
    Brodsky RA, Mukhina GL, Li S, Nelson KL, Chiurazzi PL, Buckley JT, Borowitz MJ. Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using fluorescent aerolysin. Am J Clin Pathol 2000; 114: 459466.
  • 24
    Peghini PE, Fehr J. Clinical evaluation of an aerolysin-based screening test for paroxysmal nocturnal haemoglobinuria. Cytometry B 2005; 67B: 1318.
  • 25
    Sutherland DR, Kuek N, Davidson J, Barth D, Chang H, Yeo EL, Bamford S, Chin-Yee IH, Keeney M. Diagnosing PNH with FLAER and multiparameter flow cytometry. Cytometry B 2007; 72B: 167177.
  • 26
    Richards SJ, Barnett D. The role of flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria in the clinical laboratory. Clin Lab Med 2007; 27: 577590.
  • 27
    Richards SJ, Whitby L, Cullen MJ, Dickinson AJ, Granger V, Reilly JT, Hillmen P, Barnett D. Development and evaluation of a stabilized whole-blood preparation as a process control material for screening of paroxysmal nocturnal hemoglobinuria by flow cytometry. Cytometry B 2008; 76B: 4755.
  • 28
    Keeney M, Kimmel D, Brown W, Chin-Yee I, Sutherland DR. PNH testing by flow cytometry: A Canadian Multi-Centre Quality Assurance Study. Cytometry B 2010; 78B: 396 (abstract).
  • 29
    Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007; 25: 12561264.
  • 30
    Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, Petro BE, Cullen MJ, Richards SJ, Rollins SA, Mojcik CF, Rother RP. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004; 350: 552559.
  • 31
    Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, Gaya A, Coyle L, de CC, Fu CL, Maciejewski JP, Bessler M, Kroon HA, Rother RP, Hillmen P. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008; 111: 18401847.
  • 32
    Borowitz MJ, Craig F, DiGiuseppe JA, Illingworth A, Rosse W, Sutherland DR, Witter C, Richards SJ; On behalf of the Clinical Flow Cytometry Society. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow Cytometry—A consensus guideline. Cytometry B 2010; 72B: 211230.
  • 33
    Hulspas R, Dombkowski D, Preffer F, Douglas D, Kildew-Shah B, Gilbert J. Flow cytometry and the stability of phycoerythrin-tandem dye conjugates. Cytometry A 2009; 75A: 966972.
  • 34
    Battiwalla M, Hepgur M, Pan D, McCarthy PL, Ahluwalia MS, Camacho SH, Starostik P, Wallace PK. Multiparameter flow cytometry for the diagnosis and monitoring of small GPI-deficient cellular populations. Cytometry B 2010; 78B: 348356.
  • 35
    Hochsmann B, Rojewski M, Schrezenmeier H. Paroxysmal nocturnal hemoglobinuria (PNH): Higher sensitivity and validity in diagnosis and serial monitoring by flow cytometric analysis of reticulocytes. Ann Hematol 2011; 90: 887899.
  • 36
    Movalia MK, Illingworth A. Identification and clinical significance of type II granulocytes among patients with paroxysmal nocturnal hemoglobinuria (PNH) identified using multiparameter high-sensitivity flow cytometry. Blood 2009; 114( suppl 1): 3015.
  • 37
    O'Doherty U, Peng M, Gezelter S, Swiggard WJ, Betjes M, Bhardwaj N, Steinman RM. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. Immunology 1994; 82: 487493.
  • 38
    Stetler-Stevenson M, Ahmad E, Barnett D, Braylan RC, DiGiuseppe JA, Marti J, Menozzi D, Oldaker TA, Orfao de Matos A, MD, Rabellino E, Stone EC, Walker C. Clinical flow cytometric analysis of neoplastic hematolymphoid cells. Approved Guideline, 2nd ed. CLSI document H43-A2, Vol. 27, No 11 [ISBN 1-56238-635-2]. Wayne, PA: Clinical Laboratory Standards Institute; 2007.
  • 39
    Hulspas R, O'Gorman MRG, Wood BL, Gratama JW, Sutherland DR. Considerations for the control of background fluorescence in clinical cytometry. Cytometry B 2009; 76B: 355364.
  • 40
    Stetler-Stevenson M, Arthur DC, Jabbour N, Xie XY, Molldrem J, Barrett AJ, Venzon D, Rick ME. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 2001; 98: 979987.